NY-AG v. Vyera Pharmaceuticals

Vyera Pharmaceuticals, Martin Shkreli, and Kevin Mulleady allegedly stifled competition to protect the exorbitant, monopolistic pricing of the drug Daraprim (pyrimethamine). According to NY-AG, Shkreli, Mulleady, and Vyera raised the price of the drug by more than 4,000 percent overnight, to $750 per pill, after they purchased the rights to Daraprim in August 2015.

Summary generated from official New York Attorney General press release